China's medical supplies supply securitycapabilities continue to enhance
He Yaqiong, director of the ConsumerGoods Industry Department of the Ministry of Industry and InformationTechnology, said recently that China has efficiently built a unified commandsystem, production system, collection and storage system and scheduling system,normalize the work of key medical supplies, continue to carry out emergencyduty duty, focus on increasing capacity, stable production, coordinate multipleresources, and promote the medical supplies supply security capacity has beenenhanced to effectively protect the epidemic prevention and control needs.
For the recent domestic epidemicmulti-point distribution, frequent occurrence in many places, He Yaqiong said,the first time to communicate with the provinces where the epidemic occurred,strengthen the production of new coronavirus detection reagents, protectivesupplies, therapeutic drugs and vaccines and other key medical suppliesscheduling, close tracking and monitoring of the production and supply of keyenterprises. So far, the antigen detection key production enterprises weeklyproduction capacity of more than 500 million copies, N95 / KN95 mask keyproduction enterprises weekly production capacity of more than 100 million,protective clothing key production enterprises weekly production capacity ofmore than 3 million pieces, the new coronavirus vaccine annual productioncapacity of more than 7 billion doses, production of more than 5.5 billiondoses, to meet the needs of the current epidemic prevention and controlsituation.
He Yaqiong said, will continue to improvethe production scheduling and supply of key medical supplies to strengthen thesupply and demand for accurate docking, to ensure timely and adequate supply;closely track the progress of new detection reagents, therapeutic drugs andvaccine development and marketing, timely guidance to enterprises to preparefor large-scale production; support enterprises to carry out internationalcooperation, to assist developing countries to enhance local productioncapacity, to make more for the global fight against the new crown pneumoniaepidemic China's contribution.
He Yaqiong revealed that it willaccelerate the implementation of the "14th Five-Year Plan" for thedevelopment of the pharmaceutical industry, accelerate the industrialization ofinnovative achievements, carry out actions to strengthen the pharmaceuticalindustry chain and complement the chain, focus on weak links, support upstreamand downstream enterprises in the industry chain to carry out collaborativeresearch, continue to improve the manufacturing level of the pharmaceuticalindustry, and build a number of high-standard API centralized production base .
Looking for chemical products? Let suppliers reach out to you!
2026-07-02
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
6th Drug Safety Symposium 2026 to Focus on “Beyond Algorithms & Assumptions, What Actually Matters in Pharmacovigilance”
-
Roche Acquires Carmot for $3.1 Billion to Enter Obesity Drug Market
-
Two departments issued a document to guidethe strengthening of drug cases investigation and handling
-
National Health Care Commission: 50% of thecountry's public hospitals above the second level have carried out appointmentdiagnosis and treatment services
-
India starts testing a pharmaceuticalcompany's exports of cough syrup
-
Inmanar Announces Several BreakthroughSequencing Innovations
-
244 medical device concept stocks roseindustry insiders said the process of domestic replacement is expected toaccelerate
-
Rare diseases pose a challenge to thepharmaceutical industry
-
Pfizer's $11.6 Billion Double-acting Migraine Drug Generates $318 Million in First-half Revenue
-
An Insight Into Top 5 Environmental Impact Of Drugs
Recommend Reading
-
India Strengthens Drug Approval Oversight with Expanded CDSCO Powers
-
Pfizer Sues Metsera and Novo Nordisk Over Rival Obesity Drug Strategy
-
Strides Pharma Reports Strong Q2 as Net Profit Surges 82%
-
Pharmaceutical Tariffs Put Ingredients Back in Focus
-
IPEC Updates Excipient Qualification Guidance
-
Costs Decline, PC Prices Remain High and Fluctuate in Early April
-
Multiple Negative Factors Weigh on Butadiene in April, Driving Prices Lower
-
Multiple Factors Interwoven, Short-Term Fluctuations in Polyethylene
-
This Week, the Price of Polyester Bottle Chips First Increased and Then Decreased, Falling Within the Week
-
Applications of Diphenyl Cyanide